Cellular senescence is immunogenic and promotes anti-tumor immunity

dc.contributor.authorMarin, Ines
dc.contributor.authorBoix, Olga
dc.contributor.authorGarcia Garijo, Andrea
dc.contributor.authorSirois, Isabelle
dc.contributor.authorCaballe, Adrià
dc.contributor.authorZarzuela, Eduardo
dc.contributor.authorRuano, Irene
dc.contributor.authorStephan-Otto Attolini, Camille
dc.contributor.authorPrats, Neus
dc.contributor.authorLópez Domínguez, José A.
dc.contributor.authorKovatchev, Marta
dc.contributor.authorGarralda, Elena
dc.contributor.authorMuñoz, Javier
dc.contributor.authorCaron, Etinne
dc.contributor.authorAbad, María
dc.contributor.authorGros, Alena
dc.contributor.authorPietrocola, Federico
dc.contributor.authorSerrano Marugán, Manuel
dc.date.accessioned2023-01-31T14:35:55Z
dc.date.available2023-01-31T14:35:55Z
dc.date.issued2022-07-31
dc.date.updated2023-01-30T16:09:22Z
dc.description.abstractCellular senescence is a stress response that activates innate immune cells, but little is known about its interplay with the adaptive immune system. Here, we show that senescent cells combine several features that render them highly efficient in activating dendritic cells (DCs) and antigen-specific CD8 T cells. This includes the release of alarmins, activation of interferon signaling, enhanced MHC class I machinery, and presentation of senescence-specific self-peptides that can activate CD8 T cells. In the context of cancer, immunization with senescent cancer cells elicits strong anti-tumor protection mediated by DCs and CD8 T cells. Interestingly, this protection is superior to immunization with cancer cells undergoing immunogenic cell death. Finally, the induction of senescence in human primary cancer cells also augments their ability to activate autologous antigen-specific tumor-infiltrating CD8 lymphocytes. Our study indicates that senescent cancer cells can be exploited to develop efficient and protective CD8-dependent anti-tumor immune responses.
dc.format.extent22 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idimarina6569102
dc.identifier.issn2159-8290
dc.identifier.pmid36302218
dc.identifier.urihttps://hdl.handle.net/2445/192884
dc.language.isoeng
dc.publisherAmerican Association for Cancer Research
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1158/2159-8290.CD-22-0523
dc.relation.ispartofCancer Discovery, 2023, vol. 13, num. 2, p. 410-431
dc.relation.urihttps://doi.org/10.1158/2159-8290.CD-22-0523
dc.rightscc by-nc-nd (c) Marin, Ines et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.sourceArticles publicats en revistes (Institut de Recerca Biomèdica (IRB Barcelona))
dc.subject.classificationCèl·lules canceroses
dc.subject.classificationImmunitat cel·lular
dc.subject.otherCancer cells
dc.subject.otherCellular immunity
dc.titleCellular senescence is immunogenic and promotes anti-tumor immunity
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
Marin_Cancer Discovery_2023.pdf
Mida:
16.39 MB
Format:
Adobe Portable Document Format